Sage Faces Multiple Moments Of Truth For Zuranolone, GABA Modulation
Parkinson’s Data For NMDA Modulator Also On Tap Before Year’s End
Executive Summary
Before pivotal depression data in 2021 attempt to redeem zuranolone after a failed Phase III study, the company will report Phase II results for next-gen GABA modulator SAGE-324 in essential tremor.
You may also be interested in...
Sage/Biogen Zuranolone Study Shows More Efficacy, But Higher Toxicity
Data from SHORELINE’s 50mg cohort sparked mixed opinions from analysts, with some suggesting they still showed a risk-benefit profile that could challenge the drug commercially.
Looking Past Aduhelm, Biogen Puts Pipeline On Display
In an attempt to show Biogen has more than its troubled Alzheimer’s drug Aduhelm to drive revenue growth, the company’s R&D Day highlighted several programs from its portfolio of 33 clinical-stage assets.
Biogen/Sage’s Zuranolone Data May Not Be Enough For Tough Commercial Landscape
The drug may have enough efficacy for approval, but data fell short of the benchmark seen as necessary for commercial adoption